DXCARTES

OFFICIAL TITLE: NEOADYUVANT LETROZOLE AND PALBOCICLIB IN PATIENTS WITH STAGE II-IIB BREAST CANCER, HR (+), HER2 (-) PHENOTYPE AND PRE-TREATMENT RECURRENCE SCORE (RS) RESULT 18-25 OR 26-100 BY ONCOTYPE DX BREAST RS ASSAY. ANALYSIS OF RS AND PATHOLOGICAL CHANGES AT SURGERY.

PROJECT DETAILS

THIS IS AN INTERNATIONAL, OPEN-LABEL, MULTICENTER PHASE II CLINICAL TRIAL PRIMARY OBJECTIVE: TO EXPLORE AFTER 6 MONTHS OF TREATMENT THE ABILITY OF PALBOCICLIB IN COMBINATION WITH LETROZOLE TO INDUCE GLOBAL MOLECULAR CHANGES MEASURED BY EITHER THE ONCOTYPE DX BREAST RECURRENCE SCORE® (THE “ASSAY”) TEST RESULT AT SURGERY (POST-TREATMENT RECURRENCE SCORE® (RS) RESULT), OR PATHOLOGICAL COMPLETE RESPONSE (PCR) IN PATIENTS WITH AGGRESSIVE LUMINAL TUMORS (PRE-TREATMENT RS RESULT 18-25 OR 26-100, AND KI67>20).

 

DXCARTES AT CLINICALTRIALS.GOV

TUMOR TYPE

PHASE

BREAST

II

66

25

Spain, Portugal

N

SITES

COUNTRY

STATUS

Recruiting

AACR 2019 – DOWNLOAD THE POSTER

DXCARTES SITES

Instituto Valenciano de Oncología (IVO)

SPAIN

Hospital Clínico Universitario de Valencia

SPAIN

Institut Català d' Oncologia L'Hospitalet (ICO)

SPAIN

Hospital Arnau de Vilanova de Valencia

SPAIN

Hospital Universitario Arnau de Vilanova de Lleida

SPAIN

Hospital Universitario Reina Sofía

SPAIN

Hospital Universitario Ramón y Cajal

SPAIN

Hospital Universitario Virgen de la Victoria

SPAIN

Instituto Oncológico Baselga - Hospital Quiron Salud Barcelona

SPAIN

Onkologikoa

SPAIN

Institut Català d' Oncologia Badalona (ICO)

SPAIN

Hospital Universitario Miguel Servet

SPAIN

Hospital Universitario Virgen del Rocío

SPAIN

Hospital del Mar

SPAIN

Complejo Hospitalario de Jaén

SPAIN

Hospital Universitari Vall D'Hebron

SPAIN